Inspiremd, Inc. (NSPR)

Trade NSPR now with
1/6/2020 8:22:10 AM InspireMD Anticipates Preliminary Revenue For Q4 Of $1 Mln-$1.025 Mln
9/19/2019 11:32:31 PM InspireMD Prices Public Offering Of 2.78 Mln Units At $1.80/unit
9/9/2019 8:26:10 AM InspireMD Says Working Closely With The FDA On Providing Bench Testing Information To Secure Approval For IDE
4/4/2019 6:04:38 AM InspireMD Announces Pricing Of 486,957 Shares At $5/Shr
2/19/2019 7:42:34 AM InspireMD Q4 Net Loss $2.21 Mln Or $0.05/Shr Vs Loss Of $1.5 Mln Or $7.38/Shr Last Year
11/29/2018 8:07:03 AM Inspire Announces Positive Long-Term Safety And Efficacy Data From Ongoing CGuard EPS Registries
11/6/2018 7:14:27 AM InspireMD Q3 Net Loss $2.01 Mln Or $0.05/Shr Vs Loss Of $2.09 Mln Or $6.56/Shr Last Year
9/27/2018 9:30:40 AM InspireMD Announces Presentation Of Preliminary Cumulative Three-Year CGuard EPS Safety And Efficacy Data
9/24/2018 8:13:28 AM InspireMD Announces Regulatory Approval Of CGuard Embolic Prevention System In Mexico
9/17/2018 8:15:26 AM InspireMD Announces Issuance Of U.S. Patents For Proprietary MicroNet Stent Jacket And Related Drug Eluting Technology
7/23/2018 8:42:35 AM InspireMD Establishes First Two Centers Of Excellence At Hospitals In Europe
6/29/2018 10:25:33 AM InspireMD Prices Underwritten Public Offering Of 33.33 Mln Units At $0.30/unit
5/30/2018 7:37:26 AM InspireMD Reports On Expanded 2 Year Follow-up Results From PARADIGM Clinical Study Using CGuard EPS
5/16/2018 8:13:20 AM InspireMD Gets Regulatory Approval For Both CGuard EPS And MGuard Prime In Ecuador